Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1001193112 | 10011931 | 12 | F | 20140127 | 20140620 | 20140314 | 20140630 | EXP | PHHO2014NZ002978 | NOVARTIS | 72.88 | YR | F | Y | 60.90000 | KG | 20140630 | N | MD | NZ | NZ |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1001193112 | 10011931 | 1 | PS | AFINITOR | 1 | ORAL | 10 MG, QD | 5010 | MG | D | 22334 | 10 | MG | TABLET | QD | ||||
1001193112 | 10011931 | 2 | SS | AFINITOR | 1 | 5 MG, UNK | 5010 | MG | D | 22334 | 5 | MG | TABLET | ||||||
1001193112 | 10011931 | 3 | C | METOCLOPRAMIDE | 1 | 20 MG, Q6H | D | 0 | 20 | MG | Q6H | ||||||||
1001193112 | 10011931 | 4 | C | SALBUTAMOL | 1 | INHALATION | 2 DF (PUFFS), BID | D | 0 | 2 | DF | BID | |||||||
1001193112 | 10011931 | 5 | C | PARACETAMOL | 1 | ORAL | 1 G EVERY 20 HRS PER DAY | D | 0 | 1 | G | ||||||||
1001193112 | 10011931 | 6 | C | PANTOPRAZOLO DR RED | 2 | 40 MG, BID | D | 0 | 40 | MG | BID | ||||||||
1001193112 | 10011931 | 7 | C | NODIA//LOPERAMIDE HYDROCHLORIDE | 2 | 1-2 CAPS AS REQUIRED, MAXIMUM 8 CAPS DAILY | D | 0 | 2 | DF | QD | ||||||||
1001193112 | 10011931 | 8 | C | ASPIRIN | 1 | ORAL | 100 MG, QD | D | 0 | 100 | MG | QD | |||||||
1001193112 | 10011931 | 9 | C | SYMBICORT TU | 1 | INHALATION | 1 DF (PUFF), BID | D | 0 | 1 | DF | BID | |||||||
1001193112 | 10011931 | 10 | C | ARROW-RANITIDINE | 2 | ORAL | 150 MG, BID | D | 0 | 150 | MG | BID | |||||||
1001193112 | 10011931 | 11 | C | NEO-MERCAZOLE | 1 | ORAL | 5 MG, BID | D | 0 | 5 | MG | BID | |||||||
1001193112 | 10011931 | 12 | C | PLENDIL ER | 1 | ORAL | 10 MG, QD | D | 0 | 10 | MG | QD | |||||||
1001193112 | 10011931 | 13 | C | METOPROLOL | 1 | ORAL | 47.5 MG, QD | D | 0 | 47.5 | MG | QD | |||||||
1001193112 | 10011931 | 14 | C | ACCURETIC | 1 | ORAL | 1 DF, QD (10MG/12.5 MG, QD) | U | 0 | 1 | DF | QD | |||||||
1001193112 | 10011931 | 15 | C | RANITIDINE | 1 | ORAL | 150 MG, BID | D | 0 | 150 | MG | BID | |||||||
1001193112 | 10011931 | 16 | C | BUDESONIDE W/FORMOTEROL FUMARATE | 1 | BID | D | 0 | |||||||||||
1001193112 | 10011931 | 17 | C | FELODIPINE | 1 | ORAL | 10 MG, QD | D | 0 | 10 | MG | QD | |||||||
1001193112 | 10011931 | 18 | C | METFORMIN | 1 | ORAL | 500 MG, BID | U | 0 | 500 | MG | BID | |||||||
1001193112 | 10011931 | 19 | C | OMEPRAZOLE | 1 | ORAL | 40 MG, QD | D | 0 | 40 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
1001193112 | 10011931 | 1 | Pancreatic neuroendocrine tumour metastatic |
1001193112 | 10011931 | 3 | Nausea |
1001193112 | 10011931 | 6 | Peptic ulcer |
1001193112 | 10011931 | 7 | Diarrhoea |
1001193112 | 10011931 | 13 | Blood pressure |
1001193112 | 10011931 | 15 | Peptic ulcer |
1001193112 | 10011931 | 16 | Asthma |
1001193112 | 10011931 | 17 | Blood pressure |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
1001193112 | 10011931 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
1001193112 | 10011931 | Duodenal ulcer | |
1001193112 | 10011931 | Gastroenteritis aeromonas | |
1001193112 | 10011931 | Oesophagitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
1001193112 | 10011931 | 1 | 20121009 | 20140221 | 0 | |
1001193112 | 10011931 | 2 | 20140304 | 20140402 | 0 |